Loading clinical trials...
Loading clinical trials...
Conditions
Interventions
Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) and personalised breast and ovarian cancer risk
Locations
1
United Kingdom
Wolfson Institute of Population Health, Queen Mary University of London
London, United Kingdom
Start Date
December 18, 2025
Primary Completion Date
December 1, 2029
Completion Date
December 1, 2040
Last Updated
March 27, 2026
NCT06939049
NCT06786949
NCT04082117
NCT07014553
NCT05848856
NCT02155777
Lead Sponsor
Queen Mary University of London
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions